Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VDR (Velcade, Doxil, Rituxan) in Relapsed/Refractory DLBCL
NCT00851552Phase 2Terminated
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Jan 2009
- Primary completion
- Sep 2011
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib in diffuse large B-cell lymphoma (DLBCL), sponsored by Roswell Park Comprehensive Cancer Center. Started Jan 2009; status: terminated.
02
Drugs
bortezomib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT00851552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00851552.